Search by Drug Name or NDC
NDC 65162-0749-34 Rivastigmine 13.3 mg/24h Details
Rivastigmine 13.3 mg/24h
Rivastigmine is a TRANSDERMAL PATCH in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amneal Pharmaceuticals LLC. The primary component is RIVASTIGMINE.
MedlinePlus Drug Summary
Rivastigmine transdermal patches are used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease (a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Transdermal rivastigmine is also used to treat dementia in people with Parkinson's disease (a brain system disease with symptoms of slowing of movement, muscle weakness, shuffling walk, and loss of memory). Rivastigmine is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory and thinking) by increasing the amount of a certain natural substance in the brain.
Related Packages: 65162-0749-34Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Rivastigmine Transdermal Patch
Product Information
| NDC | 65162-0749 |
|---|---|
| Product ID | 65162-749_758e7e2b-8afb-4869-8fa9-c53a6c62e174 |
| Associated GPIs | 62051040008540 |
| GCN Sequence Number | 069938 |
| GCN Sequence Number Description | rivastigmine PATCH TD24 13.3MG/24H TRANSDERM |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 33208 |
| HICL Sequence Number | 034884 |
| HICL Sequence Number Description | RIVASTIGMINE |
| Brand/Generic | Generic |
| Proprietary Name | Rivastigmine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Rivastigmine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | PATCH |
| Route | TRANSDERMAL |
| Active Ingredient Strength | 13.3 |
| Active Ingredient Units | mg/24h |
| Substance Name | RIVASTIGMINE |
| Labeler Name | Amneal Pharmaceuticals LLC |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA207308 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 65162-0749-34 (65162074934)
| NDC Package Code | 65162-749-34 |
|---|---|
| Billing NDC | 65162074934 |
| Package | 30 PATCH in 1 CARTON (65162-749-34) / 24 h in 1 PATCH |
| Marketing Start Date | 2015-06-30 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.96723 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | RIVASTIGMINE 13.3 MG/24HR PTCH |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |